A carregar...
γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct
γ‐Secretase inhibitors (GSIs) are being actively repurposed as cancer therapeutics based on the premise that inhibition of NOTCH1 signaling in select cancers is therapeutic. Using novel assays to probe effects of GSIs against a broader panel of substrates, we demonstrate that clinical GSIs are pharm...
Na minha lista:
| Publicado no: | EMBO Mol Med |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5494507/ https://ncbi.nlm.nih.gov/pubmed/28539479 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201607265 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|